{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:17:25Z","timestamp":1787584645526,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274273"],"award-info":[{"award-number":["82274273"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81774092"],"award-info":[{"award-number":["81774092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtct.2025.12.942","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T23:41:43Z","timestamp":1771717303000},"page":"590.e1-590.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel FABT-Based Conditioning Regimen With Haploidentical Transplantation for Severe Aplastic Anemia: A Prospective, Single-Center, Phase II Clinical Trial"],"prefix":"10.1016","volume":"32","author":[{"given":"Wenbin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6269-871X","authenticated-orcid":false,"given":"Zhengwei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuechao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonglin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dijiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5912-2633","authenticated-orcid":false,"given":"Baodong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.12.942_bib0001","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12185-024-03715-1","article-title":"Aplastic anemia: history and recent developments in diagnosis and treatment","volume":"119(3)","author":"Onishi","year":"2024","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2025.12.942_bib0002","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjh.17403","article-title":"Acquired severe aplastic anemia: how medical therapy evolved in the 20th and 21st centuries","volume":"194(6)","author":"Scheinberg","year":"2021","journal-title":"Br J Hematol"},{"key":"10.1016\/j.jtct.2025.12.942_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106266","article-title":"Comparison of frontline treatment with intensive immunosuppression therapy and HLA-haploidentical hematopoietic stem cell transplantation for young patients with severe aplastic anemia - a meta analysis","volume":"88","author":"Geng","year":"2020","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.942_bib0004","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.942_bib0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.13853","article-title":"Guidelines for the diagnosis and management of adult aplastic anemia","volume":"172","author":"Killick","year":"2016","journal-title":"Br J Hematol"},{"key":"10.1016\/j.jtct.2025.12.942_bib0006","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","article-title":"How I treat acquired aplastic anemia","volume":"129(11)","author":"Bacigalupo","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.942_bib0007","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.12.942_bib0008","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41409-020-01169-7","article-title":"Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges","volume":"56(4)","author":"Xu","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2025.12.942_bib0009","first-page":"175","article-title":"Allogeneic, syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas\u2013Baltimore experiences","volume":"78","author":"Santos","year":"1987","journal-title":"Acta Hematol"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.942_bib0010","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/bloodadvances.2020001729","article-title":"Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide","volume":"4","author":"DeZern","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.942_bib0011","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbmt.2016.12.628","article-title":"Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia","volume":"23","author":"DeZern","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.942_bib0012","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(22)00206-X","article-title":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anemia in the USA (BMT CTN 1502): a multicenter, single-arm, phase 2 trial","volume":"9","author":"DeZern","year":"2022","journal-title":"Lancet Hematol"},{"key":"10.1016\/j.jtct.2025.12.942_bib0016","doi-asserted-by":"crossref","unstructured":"Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Blood Marrow Transplant. 2015;21(3):389\u2013401.","DOI":"10.1016\/j.bbmt.2015.02.025"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.942_bib0017","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","article-title":"Regimen-related toxicity in patients undergoing bone marrow transplantation","volume":"6","author":"Bearman","year":"1988","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.942_bib0026","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356152","article-title":"Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF\/ATG induced GVHD protective activity and improve haploidentical transplant outcomes","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.942_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.942_bib0019","doi-asserted-by":"crossref","first-page":"429.e1","DOI":"10.1016\/j.jtct.2021.02.014","article-title":"Haploidentical peripheral stem cell transplantation for young patients with severe aplastic anemia using post-transplantation cyclophosphamide and methotrexate","volume":"27","author":"Yang","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.942_bib0015","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.bbmt.2020.07.028","article-title":"Addition of thiotepa to total body irradiation and cyclophosphamide conditioning for allogeneic hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia","volume":"26","author":"Chinnabhandar","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.942_bib0027","doi-asserted-by":"crossref","first-page":"e952","DOI":"10.1097\/HS9.0000000000000952","article-title":"Thiotepa-busulfan-fludarabine compared to treosulfan-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with acute myeloid leukemia in remission: a study from the Acute Leukemia Working Party of the EBMT","volume":"7","author":"Saraceni","year":"2023","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.942_bib0022","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/cncr.27761","article-title":"Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.942_bib0013","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41409-020-0869-6","article-title":"Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies","volume":"55","author":"Kalwak","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.jtct.2025.12.942_bib0014","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2012-03-417998","article-title":"A novel conditioning regimen improves outcomes in \u03b2-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation","volume":"120","author":"Li","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.12.942_bib0036","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.critrevonc.2018.05.017","article-title":"Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-a systematic review and meta-analysis","volume":"133","author":"Yu","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.942_bib0039","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bmt.1704325","article-title":"Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection","volume":"33","author":"Dulley","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.942_bib0020","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.942_bib0035","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.bbmt.2014.06.028","article-title":"Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia","volume":"20","author":"Clay","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.942_bib0040","doi-asserted-by":"crossref","first-page":"331.e1","DOI":"10.1016\/j.jtct.2021.01.018","article-title":"Haploidentical transplantation with modified post-transplantation cyclophosphamide for patients with primary aplastic anemia: a multicenter experience","volume":"27","author":"Li","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.942_bib0029","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2011-02-334953","article-title":"Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia","volume":"118","author":"Sanders","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.12.942_bib0021","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation","volume":"13(1)","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2025.12.942_bib0037","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3389\/fimmu.2019.02516","article-title":"Granulocyte colony-stimulating factor-primed unmanipulated haploidentical blood and marrow transplantation","volume":"10","author":"Chang","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.942_bib0030","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/bmt.2015.20","article-title":"Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study","volume":"50","author":"Esteves","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.942_bib0031","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjh.14225","article-title":"Haplo-identical transplantation for acquired severe aplastic anemia in a multicenter prospective study","volume":"175","author":"Xu","year":"2016","journal-title":"Br J Hematol"},{"key":"10.1016\/j.jtct.2025.12.942_bib0032","doi-asserted-by":"crossref","first-page":"739561","DOI":"10.3389\/fonc.2021.739561","article-title":"Inefficacy of immunosuppressive therapy for severe aplastic anemia progressing from non-SAA: improved outcome after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.942_bib0033","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/s41409-019-0773-0","article-title":"Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party","volume":"55","author":"Prata","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.942_bib0024","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.bbmt.2018.07.008","article-title":"Reduced-intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies","volume":"24","author":"Law","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.942_bib0041","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/jmv.24989","article-title":"Serologic and viral genome prevalence of HSV, EBV, and HCMV among healthy adults in Wuhan, China","volume":"90","author":"Wen","year":"2018","journal-title":"J Med Virol"},{"issue":"25","key":"10.1016\/j.jtct.2025.12.942_bib0042","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.942_bib0034","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-017-0398-y","article-title":"Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant","volume":"10","author":"Xu","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.942_bib0038","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s41409-022-01682-x","article-title":"Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anemia","volume":"57","author":"Xu","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.942_bib0043","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.942_bib0044","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2007-03-079665","article-title":"Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease","volume":"110","author":"Bernaudin","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.942_bib0045","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bbmt.2014.11.005","article-title":"A reduced-toxicity regimen is associated with durable engraftment and clinical cure of nonmalignant genetic diseases among children undergoing blood and marrow transplantation with an HLA-matched related donor","volume":"21","author":"Mahadeo","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.942_bib0046","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/bmt.2014.84","article-title":"Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease","volume":"49","author":"Bhatia","year":"2014","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725026028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725026028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:07:04Z","timestamp":1780312024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725026028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666636725026028"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.942","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel FABT-Based Conditioning Regimen With Haploidentical Transplantation for Severe Aplastic Anemia: A Prospective, Single-Center, Phase II Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}